Honda and Renesas Collaborate for Next-Gen Software-Defined Vehicles in 2025
Revance's Botox Rival Receives USFDA Nod
By Indu Tyagi Ketan , 19 October, 2022
DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines.
The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.
Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after, the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter.
In a separate report, Goldman Sachs predicted that Revance's Daxxify will cost about 30% more than its competitors, even though pricing has not yet been made public. This cost considers the extended value proposition for both doctors and patients. Revance's stock rose 18% in September post the FDA's approval, which is expected to end Botox's long-standing dominance in the aesthetics industry.
FDA Approves DaxibotulinumtoxinA (Daxxify)
Latest News
Honda and Renesas Collaborate for Next-Gen Software-Defined Vehicles in 2025
In January 2025, Honda Motor Co., Ltd. and Renesas Electronics Corporation declared a strategic collaboration to create a high-performance system on a chip (SoC) designed for Software Defined Vehicles (SDVs). This cooperation is intended to bolster…
NVIDIA's Mega Omniverse Master Plan: Revolutionizing Robotics and AI by 2025
 In 2025, NVIDIA is set to transform AI and robotics with its Mega Omniverse Blueprint, a framework for designing, simulating, and optimizing robot fleets within the digital twins of industrial environments. This new initiative combines NVIDIA's…
How Vaccines Helped Eradicate Deadly Diseases – A 2025 Breakthrough
Public health has benefited dramatically from vaccinations, which have helped completely eradicate or significantly lower the frequency of lethal illnesses. Vaccines will still be among the most potent weapons available in 2025 to stop global…
Oil Prices Crash in 2025: Biggest Weekly Drop Amid Tariffs & Oversupply
Oil prices stay on track as United States (U.S.) sanctions on Canada and Mexico keep diverting the market and stable supply levels support a significant weekly decline in 2025. Reuters said this is the biggest weekly decline since October…
Quadric and Denso Team Up to Progress Automotive AI Semiconductors for 2025
The automotive industry will benefit significantly from strategic partnerships in artificial intelligence (AI) and its use in cars. AI integration into automobiles is projected to improve considerably in the year 2025 due to the formation of various…
Indu Tyagi Ketan
Chief Strategy Officer
Latest News
NVIDIA's Mega Omniverse Master Plan: Revolutionizing Robotics and AI by 2025
How Vaccines Helped Eradicate Deadly Diseases – A 2025 Breakthrough
Oil Prices Crash in 2025: Biggest Weekly Drop Amid Tariffs & Oversupply
Quadric and Denso Team Up to Progress Automotive AI Semiconductors for 2025
